Synthesis of PEGylated cationic curdlan derivatives with enhanced biocompatibility

References

• Ku SH, Jo SD, Lee YK, et al. Chemical and structural modifications of RNAi therapeutics. Adv Drug Deliv Rev. 2016;104:16–28.
   PubMed Web of Science ®Google Scholar
• Erdene-Ochir T, Ganbold T, Zandan J, et al. Alkylation enhances biocompatibility and siRNA delivery efficiency of cationic curdlan nanoparticles. Int J Biol Macromol. 2020;143:118–125.
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811.
   PubMed Web of Science ®Google Scholar
• Couzin J. Breakthrough of the year. Small RNAs make big splash. Science. 2002;298(5602):2296–2297.
   PubMed Web of Science ®Google Scholar
• Shum K, Rossi J. siRNA delivery methods. New York (NY): Humana Press; 2016.
   Google Scholar
• Rao DD, Vorhies JS, Senzer N, et al. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev. 2009;61(9):746–759.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3(4):406–417.
   PubMed Web of Science ®Google Scholar
• Chakradhar S. Treatments that made headlines in 2018. Nat Med. 2018;24(12):1785–1787.
   PubMedGoogle Scholar
• Agarwal S, Simon AR, Goel V, et al. Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria. Clin Pharmacol Ther. 2020;108(1):63–72.
   PubMed Web of Science ®Google Scholar
• Scott LJ, Keam SJ. Lumasiran: First approval. Drugs. 2021;81(2):277–282.
   PubMed Web of Science ®Google Scholar
• Nikam RR, Gore KR. Journey of siRNA: clinical developments and targeted delivery. Nucleic Acid Ther. 2018;28(4):209–224.
   PubMed Web of Science ®Google Scholar
• Turner JJ, Jones SW, Moschos SA, Lindsay MA, et al. MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol Biosyst. 2007;3(1):43–50.
   PubMedGoogle Scholar
• Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9(1):57–67.
   PubMed Web of Science ®Google Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173–178.
   PubMed Web of Science ®Google Scholar
• Uludağ H, Landry B, Valencia-Serna J, et al. Current attempts to implement siRNA-based RNAi in leukemia models. Drug Discov Today. 2016;21(9):1412–1420.
   PubMed Web of Science ®Google Scholar
• Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv Drug Deliv Rev. 2013;65(1):60–70.
   PubMed Web of Science ®Google Scholar
• Shegokar R, Al Shaal L, Mishra PR. SiRNA delivery: challenges and role of carrier systems. Pharmazie. 2011;66(5):313–318.
   PubMed Web of Science ®Google Scholar
• Abou-El-Enein M, Bauer G, Reinke P. The business case for cell and gene therapies. Nat Biotechnol. 2014;32(12):1192–1193.
   PubMed Web of Science ®Google Scholar
• Braasch DA, Paroo Z, Constantinescu A, et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett. 2004;14(5):1139–1143.
   PubMed Web of Science ®Google Scholar
• Choung S, Kim YJ, Kim S, et al. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun. 2006;342(3):919–927.
   PubMed Web of Science ®Google Scholar
• Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA. 2003;9(9):1034–1048.
   PubMed Web of Science ®Google Scholar
• Amarzguioui M, Holen T, Babaie E, et al. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 2003;31(2):589–595.
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–555.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release. 2013;172(3):962–974.
   PubMed Web of Science ®Google Scholar
• Curcio M, Cirillo G, Rouaen JRC, et al. Natural polysaccharide carriers in brain delivery: challenge and perspective. Pharmaceutics. 2020;12(12):1183.
   Web of Science ®Google Scholar
• Sakr MA, Sakthivel K, Hossain T, et al. Recent trends in gelatin methacryloyl nanocomposite hydrogels for tissue engineering. J Biomed Mater Res. 2021;
   Web of Science ®Google Scholar
• Zhang YM, Yang Y, Zhang YH, et al. Polysaccharide nanoparticles for efficient siRNA targeting in cancer cells by supramolecular pKa shift. Sci Rep. 2016;6:28848.
   PubMed Web of Science ®Google Scholar
• Howard KA, Rahbek UL, Liu X, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther. 2006;14(4):476–484.
   PubMed Web of Science ®Google Scholar
• Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067–1070.
   PubMed Web of Science ®Google Scholar
• Han J, Cai J, Borjihan W, et al. Preparation of novel curdlan nanoparticles for intracellular siRNA delivery. Carbohydr Polym. 2015;117:324–330.
   PubMed Web of Science ®Google Scholar
• Wu Y, Cai J, Han J, et al. Cell type-specific delivery of RNAi by ligand-functionalized curdlan nanoparticles: balancing the receptor mediation and the charge motivation. ACS Appl Mater Interfaces. 2015;7(38):21521–21528.
   PubMed Web of Science ®Google Scholar
• Ganbold T, Baigude H. Design of mannose-functionalized curdlan nanoparticles for macrophage-targeted siRNA delivery. ACS Appl Mater Interfaces. 2018;10(17):14463–14474.
   PubMed Web of Science ®Google Scholar
• Ganbold T, Han S, Hasi A, et al. Receptor-mediated delivery of therapeutic RNA by peptide functionalized curdlan nanoparticles. Int J Biol Macromol. 2019;126:633–640.
   PubMed Web of Science ®Google Scholar
• Bao M, Ehexige E, Xu J, et al. Oxidized curdlan activates dendritic cells and enhances antitumor immunity. Carbohydr Polym. 2021;264:117988.
   PubMed Web of Science ®Google Scholar
• Zhang R, Snyder GH. Kinetics of disulfide exchange reactions of monomer and dimer loops of cysteine-valine-cysteine peptides. Biochemistry. 1988;27(10):3785–3794.
   PubMed Web of Science ®Google Scholar
• Tong Y, Ganbold T, Baigude H. Synthesis of amphoteric curdlan derivatives for delivery of therapeutic nucleic acids. Carbohydr Polym. 2017;175:739–745.
   PubMed Web of Science ®Google Scholar
• Han J, Wang X, Liu L, et al. “Click” chemistry mediated construction of cationic curdlan nanocarriers for efficient gene delivery. Carbohydr Polym. 2017;163:191–198.
   PubMed Web of Science ®Google Scholar
• Altangerel A, Cai J, Liu L, et al. PEGylation of 6-amino-6-deoxy-curdlan for efficient in vivo siRNA delivery. Carbohydr Polym. 2016;141:92–98.
   PubMed Web of Science ®Google Scholar
• Tseng CL, Su WY, Yen KC, et al. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials. 2009;30(20):3476–3485.
   PubMed Web of Science ®Google Scholar
• Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 2013;48(3):416–427.
   PubMed Web of Science ®Google Scholar
• Saha K, Moyano DF, Rotello VM. Protein coronas suppress the hemolytic activity of hydrophilic and hydrophobic nanoparticles. Mater Horiz. 2014;2014(1):102–105.
   PubMedGoogle Scholar